C4 Therapeutics, Inc. (CCCC) Stock Price & Analysis

C4 Therapeutics, Inc. (CCCC) rose 0.54% to USD 3.76 as of September 8, 2026 at 05:00 UTC, according to Nexqual real-time market data.

CCCC last closed at USD 3.76; the session ranged USD 3.66–3.84 on volume of 2,363,367 shares. Market capitalization is —, with a 52-week range of USD 1.69–5.17 (NMS). Source: Nexqual, September 8, 2026 at 05:00 UTC.

Key Statistics (as of September 8, 2026 at 05:00 UTC)

Technical Analysis (CCCC)

Nexqual's technical model rates CCCC "SELL" based on 1 bullish and 5 bearish signals across 128 daily candles, as of September 8, 2026 at 05:00 UTC.

From C4 Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-02-26)

Key Strengths & Strategy (as disclosed to the SEC)

• Our approach provides an opportunity to streamline clinical decision-making via a focused early clinical proof-of-concept, including early validation based on pharmacodynamic markers in healthy subjects, followed by potentially significant opportunities for expansion to several diseases. 5 Table of Contents Our TORPEDO Platform Our proprietary TORPEDO platform is an important element of our leading approach to TPD.
• Leveraging our proprietary TORPEDO platform, we efficiently design and optimize small molecule protein degraders that are highly active against their desired targets by harnessing the body's natural process for destroying unwanted proteins.
• We currently are advancing two clinical programs that were developed from our proprietary TORPEDO platform and have the potential to improve patients' outcomes. ◦ Develop cemsidomide as a potential best-in-class IKZF1/3 degrader: The Phase 1 trial of cemsidomide in combination with dexamethasone demonstrated a differentiated safety profile with compelling anti-myeloma activity.
• Under the Roche Agreement, we agreed to collaborate with Roche in the research, development, manufacture, and commercialization of target-binding degrader medicines using our proprietary TORPEDO platform for the treatment of cancers and other indications.

Partnerships

• In addition, as part of the collaboration, we have agreed to make milestone payments to Betta Pharma of up to $40.0 million following our receipt of approval of a New Drug Application for CFT8919 from the FDA, with the milestone amount based on the percentage of patients in contemplated clinical trials that were enrolled by Betta Pharma and the line of therapy of the approval.
• Clinical Trials of CFT8919 in Non-Small Cell Lung Cancer In May 2023, we entered into an exclusive licensing and collaboration agreement with Betta Pharma for the development and commercialization of CFT8919 in Greater China, including mainland China, Hong Kong SAR, Macau SAR and Taiwan.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 05:00 UTC. This page is informational and not investment advice.